| Bio Roundup: An Alzheimer’s Head-Scratcher, OUTBio, GSK & Gilead Shakeups | Ben Fidler | 07/27/18 | National |
| Sangamo Bags TxCell, and a Next-Gen Cell Therapy Tech, for $84M | Ben Fidler | 07/23/18 | San Francisco |
| Not Resting on Hemophilia Biz, Bioverativ Pays $400M For True North | Ben Fidler | 05/23/17 | Boston |
| Bio Roundup: Big Apple Mo’, Checkpoint Yes and No, CAR-T Death & More | Alex Lash | 05/12/17 | National |
| Biotech Roundup: Biogen Rumors, Theranos, Electro-Drugs & More | Ben Fidler | 08/05/16 | National |
| Shire Steps Back in Hemophilia Gene Therapy Race, Scraps Baxalta Drug | Ben Fidler | 08/03/16 | Boston |
| At Big Hemophilia Meeting, More Data, and Promise, For Gene Therapy | Ben Fidler | 07/28/16 | National |
| Sean Parker To Fund CRISPR Trial, And Other Gene Edit Milestones | Alex Lash | 06/20/16 | National |
| Biotech Roundup: Deals Gone Wrong, Ethical Red Flags & Bay Goodbyes | Alex Lash | 06/03/16 | National |
| Biogen Turns To UPenn Gene Therapy Pioneers in Wide-Ranging Alliance | Ben Fidler | 05/16/16 | Boston |
| Across The Board: Ideas To Narrow Biotech’s Gender Gap | Alex Lash | 05/10/16 | National |
| With $43.5M Startup Cash, Homology Med Chases New Gene Editing Twist | Ben Fidler | 05/02/16 | Boston |
| With CRISPR in Humans On The Horizon, Will the Public Back Intellia? | Alex Lash | 04/29/16 | Boston |
| Making the Price Right: Ideas To Change Drug Costs Gain Momentum | Alex Lash | 04/05/16 | National |
| Gene Editing Execs Talk Scientific, Regulatory Hurdles At BIO Panel | Ben Fidler | 02/10/16 | Boston |
| CRISPR: The Path to Clinical Trials | Alex Harding | 01/29/16 | Boston |
| UniQure’s Shares Rise on Early Gene Therapy Data For Hemophilia | Ben Fidler | 01/07/16 | National |
| Boston Scientists Tweak CRISPR Scissors For More Precise DNA Cuts | Alex Lash | 01/06/16 | Boston |
| Stewart Parker: Biotech Thoughts On Gene Therapy, GOP & Trout Streams | Alex Lash | 12/31/15 | Seattle |
| Pharmabros, Designer Babies, And Other Final Words For 2015 | Alex Lash | 12/24/15 | National |
| Gene Edit Summit Leaders Stop Shy Of Call To Ban Germline Changes | Alex Lash | 12/03/15 | National |
| New Speakers Join Gene-Edit, Microbiome, Big Data “Disruptors” 12/10 | Alex Lash | 12/02/15 | San Francisco |
| Agenda Posted: Xconomy’s Bay Area Life Science Disruptors On Dec. 10 | Alex Lash | 11/19/15 | San Francisco |
| Join Xconomy Dec. 10 To Hear From Bay Area Life Science Disruptors | Alex Lash | 11/12/15 | San Francisco |
| Amid Nobel Prize Suspense, Making Sense Of Latest Gene-Editing News | Alex Lash | 10/06/15 | National |
| CRISPR Update Could Make Gene Edits Easier, Discoverers Say | Alex Lash | 09/25/15 | Boston |
| Gene Therapy Startup Dimension Tx Takes Crossover Cash to IPO Queue | Ben Fidler | 09/14/15 | Boston |
| West Coast Biotech Roundup: Amgen, Grizzlies, Topol, Faraday & More | Alex Lash | 09/03/15 | San Francisco |
| Shire Sends Hemophilia Gene Editing Prospects Back to Sangamo | Ben Fidler | 09/02/15 | San Francisco |
| 100 Years But Only One Drug: Sickle Cell Patients Wait For Help | Alex Lash | 08/18/15 | National |
